Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Expanding the Use of Immunoscore in Early-Stage CRC

June 20th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal Cancer

June 19th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).

Pfizer Acquires Array BioPharma in $11.4 Billion Deal

June 18th 2019

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

June 17th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Tumor Sidedness Opens Door for Personalized Therapy in Colorectal Cancer

June 17th 2019

Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.

The Clinical Utility of Immunoscore in Stage III CRC

June 14th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.

Dr. Lieu on HER2-Directed Therapy in CRC

June 14th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).

Dr. Bekaii-Saab on the Impact of the BEACON CRC Study in BRAF-Mutated CRC

June 13th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.

Future of mCRC Lies in Biomarker-Directed Therapies

June 12th 2019

Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.

Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRC

June 12th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

Management of Newly Diagnosed mCRC Driven by Molecular Markers

June 11th 2019

Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.

Dr. Nallapareddy on Treatment Options for Left- and Right-Sided CRC

June 11th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist, Rocky Mountain Cancer Centers, discusses treatment options for left- and right-sided colorectal cancer.

Dr. El-Rayes Discusses Methods of Locoregional Therapy in mCRC

June 7th 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.

Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

June 6th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Dr. Messersmith on Molecular Markers to be Aware of in CRC

June 5th 2019

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases

June 3rd 2019

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Dr. El-Rayes on Locoregional Therapy Versus Resection in CRC

May 23rd 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses considerations for locoregional therapy versus resection in patients with colorectal cancer.

Encorafenib, Binimetinib, and Cetuximab Triplet Improves OS, ORR in BRAF+ CRC

May 21st 2019

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

May 21st 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.